306 related articles for article (PubMed ID: 9533981)
1. Saquinavir. Clinical pharmacology and efficacy.
Vella S; Floridia M
Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
4. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
Plosker GL; Scott LJ
Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
[TBL] [Abstract][Full Text] [Related]
5. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.
Noble S; Faulds D
Drugs; 1996 Jul; 52(1):93-112. PubMed ID: 8799687
[TBL] [Abstract][Full Text] [Related]
6. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
8. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
10. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
Perry CM; Noble S
Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
[TBL] [Abstract][Full Text] [Related]
11. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Hsu A; Granneman GR; Bertz RJ
Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
[TBL] [Abstract][Full Text] [Related]
13. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
15. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
Lorenzi P; Yerly S; Abderrakim K; Fathi M; Rutschmann OT; von Overbeck J; Leduc D; Perrin L; Hirschel B
AIDS; 1997 Oct; 11(12):F95-9. PubMed ID: 9342060
[TBL] [Abstract][Full Text] [Related]
16. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
Harrigan PR; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner JS
AIDS; 1999 Oct; 13(14):1863-71. PubMed ID: 10513644
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and clinical experience with saquinavir.
Kravcik S
Expert Opin Pharmacother; 2001 Feb; 2(2):303-15. PubMed ID: 11336588
[TBL] [Abstract][Full Text] [Related]
18. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
19. Current knowledge and future prospects for the use of HIV protease inhibitors.
Moyle G; Gazzard B
Drugs; 1996 May; 51(5):701-12. PubMed ID: 8861542
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
